Roth Keeps Ligand (LGND) at 'Buy' Following New Captisol-Based Tech Launch
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Ligand Pharma (LGND) Reports Expanded License Agreement with CURx Pharma
September 9, 2014 8:37 AM EDTLigand Pharma (Nasdaq: LGND) has expanded its global license agreement with CURx Pharmaceuticals, Inc. to also include the development and commercialization of Ligands Captisol-enabled Lamotrigine program. Under the terms of the expanded license, Ligand will be eligible to receive $22 million in potential milestone payments,... More
